Novo Nordisk Expands R&D Facility in China
Novo Nordisk is investing $100 million to expand its R&D facilities in Beijing, China. The company estimates that the new 12,000-m2 (129,167 ft2) center will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth.
Novo Nordisk has invested $100 million in expanding its research center in Beijing, China, to 12,000 m2 (129,167 ft2).
The extra space will accommodate future growth in protein technology, biology, and pharmacology research activities, fulfilling the company’s key strategic objective to develop the full range of protein research capabilities in China. The expansion will also encourage stronger contributions from the science team in China, which currently consists of 130 scientists and is expected to increase to 200 at the new site.
The Beijing site has already contributed significantly to Novo Nordisk’s R&D portfolio in various biopharmaceutical disease areas, including diabetes.
Internal server error